vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and ROGERS COMMUNICATIONS INC (RCI). Click either name above to swap in a different company.
ROGERS COMMUNICATIONS INC is the larger business by last-quarter revenue ($978.2M vs $722.5M, roughly 1.4× Amneal Pharmaceuticals, Inc.).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Rogers Communications Inc. is a Canadian communications and media company operating primarily in the fields of wireless communications, cable television, telephony and Internet, with significant additional telecommunications, mass media, and professional sports assets. Rogers has its headquarters in Toronto, Ontario.
AMRX vs RCI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2023
| Metric | | |
|---|---|---|
| Revenue | $722.5M | $978.2M |
| Net Profit | $78.0M | — |
| Gross Margin | 44.3% | — |
| Operating Margin | — | — |
| Net Margin | 10.8% | — |
| Revenue YoY | 3.9% | — |
| Net Profit YoY | 217.0% | — |
| EPS (diluted) | $0.19 | $0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | — | ||
| Q3 25 | $784.5M | — | ||
| Q2 25 | $724.5M | — | ||
| Q1 25 | $695.4M | — | ||
| Q4 24 | $730.5M | — | ||
| Q3 24 | $702.5M | — | ||
| Q2 24 | $701.8M | — |
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $22.4M | — | ||
| Q1 25 | $12.2M | — | ||
| Q4 24 | $-31.1M | — | ||
| Q3 24 | $-156.0K | — | ||
| Q2 24 | $6.0M | — |
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | — | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | 14.4% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 13.6% | — |
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | -4.3% | — | ||
| Q3 24 | -0.0% | — | ||
| Q2 24 | 0.9% | — |
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.07 | — | ||
| Q1 25 | $0.04 | — | ||
| Q4 24 | $-0.10 | — | ||
| Q3 24 | $0.00 | — | ||
| Q2 24 | $0.02 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
RCI
Segment breakdown not available.
